 The FDA has granted Orphan Drug designation to Longeveron Incs NASDAQ: LGVN lead investigational product Lomecel-B for Hypoplastic left heart syndrome HLHS. Lomecel-B is a cell-based therapy product derived from culture-expanded medicinal signaling cells MSCs, sourced from the bone marrow of young, healthy adult donors. 